The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:c0fabea4154e7b3de2267ddd2014dbee]
0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:c0fabea4154e7b3de2267ddd2014dbee]
0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
Bio2RDF identifier
c0fabea4154e7b3de2267ddd2014dbee
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c0fabea4154e7b3de2267ddd2014dbee
measure [clinicaltrials_vocabulary:measure]
The primary endpoint for asses ...... on MDCK cells at 33 degrees C
time frame [clinicaltrials_vocabulary:time-frame]
nasal swabs obtained at days 2 post vaccination
description
0.2 ml dose of live monovalent ...... y, 2 doses given 28 days apart
identifier
clinicaltrials_resource:c0fabea4154e7b3de2267ddd2014dbee
title
The primary endpoint for asses ...... ned at days 2 post vaccination
@en
type
label
The primary endpoint for asses ...... abea4154e7b3de2267ddd2014dbee]
@en